Correction: Updated Public Health Impact and Cost Effectiveness of Recombinant Zoster Vaccine in Canadian Adults Aged 50 Years and Older
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
Correction: Updated Public Health Impact and Cost Effectiveness of Recombinant Zoster Vaccine in Canadian Adults Aged 50 Years and Older ; volume:8 ; number:5 ; day:17 ; month:7 ; year:2024 ; pages:785 ; date:9.2024
PharmacoEconomics - open ; 8, Heft 5 (17.7.2024), 785, 9.2024
- Creator
-
George, Sydney
Carrico, Justin
Hicks, Katherine A.
Loukov, Dessi
Ng, Cheryl
Regan, Jessica
Giannelos, Nikolaos
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s41669-024-00502-w
- URN
-
urn:nbn:de:101:1-2411250841378.286999952091
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:21 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- George, Sydney
- Carrico, Justin
- Hicks, Katherine A.
- Loukov, Dessi
- Ng, Cheryl
- Regan, Jessica
- Giannelos, Nikolaos
- SpringerLink (Online service)
Other Objects (12)
Updated Public Health Impact and Cost Effectiveness of Recombinant Zoster Vaccine in Canadian Adults Aged 50 Years and Older
Public Health Impact and Cost-Effectiveness of Non-live Adjuvanted Recombinant Zoster Vaccine in Canadian Adults
Cost-Effectiveness of the Adjuvant Recombinant Zoster Vaccine in Japanese Adults Aged 65 Years and Older
Post-Marketing Safety Surveillance for the Adjuvanted Recombinant Zoster Vaccine: Methodology
Skin manifestations after immunisation with an adjuvanted recombinant zoster vaccine, Germany, 2020
Zoster
![[Zoster]](https://iiif.deutsche-digitale-bibliothek.de/image/2/4f593c2d-16fb-47c5-9d92-e90d3404889f/full/!306,450/0/default.jpg)
[Zoster]
Cost-Effectiveness Analysis Update of the Adjuvanted Recombinant Zoster Vaccine in Japanese Older Adults
Acupuncture in Acute Herpes Zoster (AcuZoster)
Modelling the Public Health Burden of Herpes Zoster and the Impact of Adjuvanted Recombinant Zoster Vaccine in Five Selected Countries in Southeast Asia
XXI. Zoster.
Herpes zoster.
Updated Public Health Impact and Cost Effectiveness of Recombinant Zoster Vaccine in Canadian Adults Aged 50 Years and Older
Public Health Impact and Cost-Effectiveness of Non-live Adjuvanted Recombinant Zoster Vaccine in Canadian Adults
Cost-Effectiveness of the Adjuvant Recombinant Zoster Vaccine in Japanese Adults Aged 65 Years and Older
Post-Marketing Safety Surveillance for the Adjuvanted Recombinant Zoster Vaccine: Methodology
Skin manifestations after immunisation with an adjuvanted recombinant zoster vaccine, Germany, 2020
Zoster
[Zoster]
Cost-Effectiveness Analysis Update of the Adjuvanted Recombinant Zoster Vaccine in Japanese Older Adults
Acupuncture in Acute Herpes Zoster (AcuZoster)
Modelling the Public Health Burden of Herpes Zoster and the Impact of Adjuvanted Recombinant Zoster Vaccine in Five Selected Countries in Southeast Asia
XXI. Zoster.
Herpes zoster.
Updated Public Health Impact and Cost Effectiveness of Recombinant Zoster Vaccine in Canadian Adults Aged 50 Years and Older
Public Health Impact and Cost-Effectiveness of Non-live Adjuvanted Recombinant Zoster Vaccine in Canadian Adults
Cost-Effectiveness of the Adjuvant Recombinant Zoster Vaccine in Japanese Adults Aged 65 Years and Older
Post-Marketing Safety Surveillance for the Adjuvanted Recombinant Zoster Vaccine: Methodology
Skin manifestations after immunisation with an adjuvanted recombinant zoster vaccine, Germany, 2020
Zoster
[Zoster]
Cost-Effectiveness Analysis Update of the Adjuvanted Recombinant Zoster Vaccine in Japanese Older Adults
Acupuncture in Acute Herpes Zoster (AcuZoster)
Modelling the Public Health Burden of Herpes Zoster and the Impact of Adjuvanted Recombinant Zoster Vaccine in Five Selected Countries in Southeast Asia
XXI. Zoster.